ATLANTA — A thyroid medication is being recalled nationwide because some tablets may contain more medication than intended, according to the U.S. Food and Drug Administration.
Vitruvias Therapeutics is recalling one lot of its Thyroid Tablets, USP 30 mg after testing found the potential for the product to be super potent.
The recall involves Lot 504950, which has an expiration date of Sept. 30, 2026, according to U.S. Food and Drug Administration officials.
The affected medication was distributed nationwide to Vitruvias Therapeutics’ direct accounts between Jan. 31, 2025, and Sept. 30, 2025.
Taking too much thyroid hormone can cause hyperthyroidism, which may lead to weight loss, fatigue, nervousness, muscle weakness, high blood pressure, chest pain, a rapid heartbeat and abnormal heart rhythms, the FDA said.
Older adults, pregnant women and infants may face greater risks from excessive thyroid hormone exposure, particularly over an extended period.
The medication is used to treat hypothyroidism, or an underactive thyroid.
Vitruvias Therapeutics said it has not received any reports of adverse events related to the recall.
Officials say that consumers who are taking the recalled medication should not stop using it without first contacting their health care provider about a replacement prescription or other guidance.
Consumers with questions can contact Vitruvias Therapeutics at 256-239-9373 or safety@vitruvias.com Monday through Friday from 9 a.m. to 5 p.m. CT, while the FDA’s recall notice provides additional information about the affected product.